Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Uveal Melanoma × Ipilimumab × Clear all

Phase

Phase 2 9 Phase 1 8 Phase 1/2 5 Phase EARLY_PHASE1 1 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 15 Carcinoma, Non-Small-Cell Lung 8 Carcinoma, Renal Cell 7 Kidney Neoplasms 4 Stomach Neoplasms 3 Mesothelioma 3 Diabetes Mellitus, Insulin-Dependent, 12 3 Skin Neoplasms 2 Prostatic Neoplasms 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Neoplasm Metastasis 2 Mesothelioma, Malignant 2 Lung Neoplasms 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Hepatocellular 2 Various Advanced Cancer 1 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Recurrence 1 Non-Small Cell Lung Cancer Metastatic 1 Neoplasms 1 Lymphatic Metastasis 1 Liver Neoplasms 1 Colonic Neoplasms 1

Interventions

Melphalan 3 tebentafusp 1 sargramostim 1 fotemustine 1 aflibercept 1 Ranibizumab 1 Nivolumab 1 Neoadjuvant Therapy 1 Melatonin 1 MART-1 Antigen 1 Ipilimumab 1 Eye Enucleation 1 Colony-Stimulating Factors 1 Chemotherapy, Cancer, Regional Perfusion 1 Brachytherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06519266 2024-11-25

SCANDIUM-III

Vastra Gotaland Region

Phase 3 Recruiting

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡